The global cancer biomarkers market size reached US$ 27.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 77.0 Billion by 2032, exhibiting a growth rate (CAGR) of 11.7% during 2024-2032. More Info:- https://www.imarcgroup.com/cancer-biomarkers-market

1. Global Cancer
Biomarkers Market
Research and Forecast
Report 2024-2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved

2. About IMARC Group
International Market Analysis Research and Consulting Group is a leading adviser on management
strategy and market research worldwide. We partner with clients in all regions and industry
verticals to identify their highest-value opportunities, address their most critical challenges, and
transform their businesses.
IMARC’s information products include major market, scientific, economic and technological
developments for business leaders in pharmaceutical, industrial, and high technology
organizations. Market forecasts and industry analysis for biotechnology, advanced materials,
chemicals, food and beverage, travel and tourism, nanotechnology and novel processing methods
are at the top of the company’s expertise.
IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and
markets with close cooperation at all levels of the client organization. This ensures that our clients
achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting
results.

3. Report Highlight
and Description
According to the latest report by IMARC Group, titled "Cancer Biomarkers
Market: Global Industry Trends, Share, Size, Growth, Opportunity and
Forecast 2024-2032," the global cancer biomarkers market size reached US$
27.9 Billion in 2023.
Cancer biomarkers refer to biological molecules produced by the cancer cells
or other cells in the body in response to cancer. Enzymes, peptides, proteins,
nucleic acids, genes, and specific cells are some of the most commonly used
biomarkers. They indicate the presence of cancer in the blood, tissues, or
other fluids of the body.
They are widely used for disease diagnosis, screening, establishing prognosis,
monitoring treatment, and detecting the chances of relapse. They also assist
healthcare professionals in tracking the progression of the disease, identifying
invasive and non-invasive tumors, and recording treatment efficacy. As a
result, cancer biomarkers find extensive applications as prognostics, surrogate
endpoints, diagnostics, and personalized medicines across the healthcare
industry.
Request for a PDF sample of this report:
https://www.imarcgroup.com/cancer -biomarkers-market/requestsample

4. Report Description
Global Cancer Biomarkers Market Trends:
The rising incidences of cancer, such as breast, prostate, cervical, lung, and colorectal cancer, represent the
primary factor driving the market growth. Besides this, the increasing usage of cancer biomarkers in early cancer
detection, managing treatment, and predicting accurate outcomes is another major growth-inducing factor.
Additionally, due to the lack of standard diagnosis, there has been a significant shift toward personalized
medicine for cancer treatment. In line with this, the growing awareness regarding the importance of early cancer
diagnosis among healthcare professionals and patients has augmented the demand for cancer biomarkers.
Furthermore, several key players are extensively investing in research and development (R&D) activities to
introduce innovative diagnostic products.
Along with this, recent technological advancements in genetic biomarker discovery, such as next-generation
sequencing (NGS), polymerase chain reaction (PCR), gene expression profiling (microarray), and proteomics,
have propelled market growth. Other factors, including the rising regulatory approvals of novel drugs and
diagnostics, improving healthcare infrastructure, surging government funding for drug development, increasing
consumer healthcare spending, and availability of favorable reimbursement policies, are also providing a positive
thrust to the market growth.
Looking forward, the market to reach US$ 77.0 Billion by 2032, expanding at a CAGR of 11.7% during 2024-
2032
View Report TOC, Figures and Tables: https://www.imarcgroup.com/cancer-biomarkers-market

5. Report
Segmentation
Breakup by Profiling Technology:
• Omic Technologies
• Imaging Technologies
• Immunoassays
• Cytogenetics
Breakup by Biomolecule:
• Genetic Biomarkers
• Protein Biomarkers
• Glyco-Biomarkers
Breakup by Cancer Type:
• Breast Cancer
• Lung Cancer
• Colorectal Cancer

6. Report
Segmentation
• Prostate Cancer
• Stomach Cancer
• Others
Breakup by Application:
• Diagnostics
• Prognostics
• Risk Assessment
• Drug Discovery and Development
• Others
Breakup by End User:
• Hospitals
• Academic and Research Institutions

7. Report
Segmentation
• Ambulatory Surgical Centers
• Diagnostic Laboratories
• Others
Breakup by Region:
• North America
• Asia-Pacific
• Europe
• Latin America
• Middle East and Africa

8. Competitive
Landscape with
Key Players
• Abbott Laboratories
• Agilent Technologies Inc.
• Becton Dickinson and Company
• bioMérieux SA
• Danaher Corporation
• F. Hoffmann-La Roche AG
• General Electric Company
• Illumina Inc.
• Qiagen N.V.
• Sino Biological Inc.
• Thermo Fisher Scientific Inc.

9. Key Questions
Answered in
the Report
What was the size of the global cancer biomarkers market in
2023?
What is the expected growth rate of the global cancer
biomarkers market during 2024-2032?
What are the key factors driving the global cancer biomarkers
market?
What has been the impact of COVID-19 on the global cancer
biomarkers market?
What is the breakup of the global cancer biomarkers market
based on the biomolecule?
What is the breakup of the global cancer biomarkers market
based on the cancer type?
What are the key regions in the global cancer biomarkers
market?
Who are the key players/companies in the global cancer
biomarkers market?

10. Table of
Contents
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Cancer Biomarkers Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Profiling Technology
6.1 Omic Technologies
6.1.1 Mark et Trends
6.1.2 Mark et Forecast
6.2 Imaging Technologies
6.2.1 Mark et Trends
6.2.2 Mark et Forecast
6.3 Immunoassays
6.3.1 Mark et Trends
6.3.2 Mark et Forecast

11. Table of
Contents
6.4 Cytogenetics
6.4.1 Mark et Trends
6.4.2 Mark et Forecast
7 Market Breakup by Biomolecule
7.1 Genetic Biomarkers
7.1.1 Mark et Trends
7.1.2 Mark et Forecast
7.2 Protein Biomarkers
7.2.1 Mark et Trends
7.2.2 Mark et Forecast
7.3 Glyco-Biomarkers
7.3.1 Mark et Trends
7.3.2 Mark et Forecast
8 Market Breakup by Cancer Type
8.1 Breast Cancer
8.1.1 Mark et Trends
8.1.2 Mark et Forecast
8.2 Lung Cancer
8.2.1 Mark et Trends
8.2.2 Mark et Forecast
8.3 Colorectal Cancer
8.3.1 Mark et Trends
8.3.2 Mark et Forecast
8.4 Prostate Cancer
8.4.1 Mark et Trends
8.4.2 Mark et Forecast
8.5 Stomach Cancer
8.5.1 Mark et Trends
8.5.2 Mark et Forecast
For more information, visit :
https://www.imarcgroup.com/cancer -biomarkers-market/toc

12. Disclaimer
© 2023 IMARC All Rights Reserved
This Publication and all it’s contents unless otherwise mentioned are copyrighted in the
name of International Market Analysis Research and Consulting (IMARC). No part of this
publication may be reproduced, repackaged, redistributed or resold in whole or in any part.
The publication may also not be used in any form or by and means graphic electronic or
mechanical, including photocopying, recording, taping or by information storage or retrieval,
or by any other form, without the express consent of International Market Analysis Research
and Consulting (IMARC).
Disclaimer: All contents and data of this publication, including forecasts, data analysis and
opinion have been based on information and sources believed to be accurate and reliable at
the time of publishing. International Market Analysis Research and Consulting makes no
representation of warranty of any kind as to the accuracy or completeness of any Information
provided. IMARC accepts no liability whatsoever for any loss or damage resulting from
opinion, errors or inaccuracies if any found this publication.
IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of
International Market Analysis Research and Consulting. All other trademarks used in this
publication are registered trademarks of their respective companies.

13. Contact Us
Visit us at :
https://www.imarcgroup.com
TELEPHONE: +1-631-791-1145
E-MAIL: sales@imarcgroup.com